中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

14 records (took 0.034 seconds)

    SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT
    1.
    发明申请
    SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT 审中-公开

    公开(公告)号：US20180065961A1

    公开(公告)日：2018-03-08

    申请号：US15806964

    申请日：2017-11-08

    Applicant: AbbVie Inc.

    Inventor： Nathaniel Catron ,  Shuang Chen ,  Yuchuan Gong ,  Geoff G. Zhang

    IPC: C07D471/04

    Abstract: Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

    SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT
    2.
    发明申请
    SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT 审中-公开

    公开(公告)号：US20200231593A1

    公开(公告)日：2020-07-23

    申请号：US16843729

    申请日：2020-04-08

    Applicant: AbbVie Inc.

    Inventor： Nathaniel Catron ,  Shuang Chen ,  Yuchuan Gong ,  Geoff G. Zhang

    IPC: C07D471/04

    Abstract: Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

    SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT
    3.
    发明申请
    SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT 审中-公开

    公开(公告)号：US20190194196A1

    公开(公告)日：2019-06-27

    申请号：US16288324

    申请日：2019-02-28

    Applicant: AbbVie Inc.

    Inventor： Nathaniel Catron ,  Shuang Chen ,  Yuchuan Gong ,  Geoff G. Zhang

    IPC: C07D471/04

    CPC classification number: C07D471/04

    Abstract: Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

    Solid dispersions containing an apoptosis-inducing agent
    4.
    发明授权
    Solid dispersions containing an apoptosis-inducing agent 有权

    公开(公告)号：US10213433B2

    公开(公告)日：2019-02-26

    申请号：US14537392

    申请日：2014-11-10

    Applicant: AbbVie Inc.

    Inventor： Nathaniel Catron ,  David Lindley ,  Jonathan M. Miller ,  Eric A. Schmitt ,  Ping Tong

    IPC: A61K31/397 ,  A61K31/5377 ,  A61K9/14 ,  A61K9/16 ,  A61K9/48 ,  A61K31/437 ,  A61K31/496

    Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

    Salts and crystalline forms of an apoptosis-inducing agent
    5.
    发明授权
    Salts and crystalline forms of an apoptosis-inducing agent 有权

    公开(公告)号：US09840502B2

    公开(公告)日：2017-12-12

    申请号：US14957097

    申请日：2015-12-02

    Applicant: AbbVie Inc.

    Inventor： Nathaniel Catron ,  Shuang Chen ,  Yuchuan Gong ,  Geoff G. Zhang

    IPC: C07D471/04

    CPC classification number: C07D471/04

    Abstract: Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

    SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
    6.
    发明申请
    SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT 审中-公开

    公开(公告)号：US20190275051A1

    公开(公告)日：2019-09-12

    申请号：US16239199

    申请日：2019-01-03

    Applicant: AbbVie Inc.

    Inventor： Nathaniel Catron ,  David Lindley ,  Jonathan M. Miller ,  Eric A. Schmitt ,  Ping Tong

    IPC: A61K31/5377 ,  A61K9/48 ,  A61K31/496 ,  A61K31/437 ,  A61K9/14 ,  A61K9/16

    Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

    SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT
    7.
    发明申请
    SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT 有权
    病毒诱导剂的口服和结晶形式

    公开(公告)号：US20160083384A1

    公开(公告)日：2016-03-24

    申请号：US14957097

    申请日：2015-12-02

    Applicant: AbbVie Inc.

    Inventor： Nathaniel Catron ,  Shuang Chen ,  Yuchuan Gong ,  Geoff G. Zhang

    IPC: C07D471/04

    CPC classification number: C07D471/04

    Abstract: Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

    Abstract translation: 盐酸盐和4-（4 - {[2-（4-氯苯基）-4,4-二甲基环己-1-烯-1-基]甲基}哌嗪-1-基）-N - （{3-硝基 -4 - [（四氢-2H-吡喃-4-基甲基）氨基]苯基} - 磺酰基）-2-（1H-吡咯并[2,3-b]吡啶-5-基氧基）苯甲酰胺是药物的合适的活性药物成分 可用于治疗以一种或多种抗凋亡Bcl-2家族蛋白（例如癌症）过表达为特征的疾病的组合物。

    SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT
    9.
    发明申请
    SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT 有权
    病毒诱导剂的口服和结晶形式

    公开(公告)号：US20140213596A1

    公开(公告)日：2014-07-31

    申请号：US14228132

    申请日：2014-03-27

    Applicant: AbbVie Inc.

    Inventor： Nathaniel Catron ,  Shuang Chen ,  Yuchuan Gong ,  Geoff G. Zhang

    IPC: C07D471/04

    CPC classification number: C07D471/04

    Abstract: Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

    Abstract translation: 盐酸盐和4-（4 - {[2-（4-氯苯基）-4,4-二甲基环己-1-烯-1-基]甲基}哌嗪-1-基）-N - （{3-硝基 -4 - [（四氢-2H-吡喃-4-基甲基）氨基]苯基} - 磺酰基）-2-（1H-吡咯并[2,3-b]吡啶-5-基氧基）苯甲酰胺是药物的合适的活性药物成分 可用于治疗以一种或多种抗凋亡Bcl-2家族蛋白（例如癌症）过表达为特征的疾病的组合物。

    SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
    10.
    发明申请
    SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT 有权

    公开(公告)号：US20220125796A1

    公开(公告)日：2022-04-28

    申请号：US17341158

    申请日：2021-06-07

    Applicant: AbbVie Inc.

    Inventor： Nathaniel Catron ,  David Lindley ,  Jonathan M. Miller ,  Eric A. Schmitt ,  Ping Tong

    IPC: A61K31/5377 ,  A61K9/16 ,  A61K9/14 ,  A61K31/496 ,  A61K31/437 ,  A61K9/48

    Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Patent Agency Ranking